小红书6月4日微博发问后账号被封,遭中国网信办调查

看来是年轻的新媒体运营人员真的不知道,洗脑很成功,党国可以放心了。

6月4日,小红书在微博(Weibo)上发帖称:“大声告诉我,今天的日期是____!”小红书总部位于上海,阿里巴巴集团控股有限公司(Alibaba Group Holding Ltd., BABA, 9988.HK, 简称:阿里巴巴)和腾讯控股有限公司(Tencent Holdings Ltd., 0700.HK, 简称﹕腾讯)均持有其股份。

上周五的这则帖子很快就被删除了;当天是中国军队镇压天安门广场学生和平抗议活动的32周年纪念日。到北京时间上周五午夜时分,小红书拥有1,400万粉丝的整个微博账号已经消失,取而代之的是一条消息,说该账户因涉嫌违反法律法规现已无法查看。

据知情人士透露,小红书正配合中国国家互联网信息办公室(简称:网信办)就此事展开内部调查。人们认为小红书是Instagram式社交媒体平台和亚马逊(Amazon)式电商网站的结合体。

目前尚不清楚小红书在社交媒体上发帖的初衷是什么,不过其中一位知情人士称,这篇帖子并无意提及1989年的事件。最近几个月,小红书在每周五都发布了类似的帖子,庆祝即将到来的周末。

Source: 小红书6月4日微博发问后账号被封,遭中国网信办调查 – 华尔街日报

Early adopters of Chinese vaccines see case surges; China plows ahead anyway

广州到现在也没公布确诊病例中疫苗接种情况。

The dramatic ramp up comes at an awkward time, however. Early adopters of China’s vaccines have seen dramatic surges in COVID-19 cases—despite high vaccination rates—and are now backing away from the country’s offerings.

In Bahrain, for instance, officials are now offering high-risk people who have already received two doses of China’s Sinopharm vaccine a third vaccine dose—but one made by Pfizer-BioNTech. The apparent vote of no confidence by officials is striking: Bahrain was one of the first countries to back and rollout Sinopharm’s vaccine, and it has had a highly successful vaccination campaign. Nearly 58 percent of the Persian Gulf country has received at least one dose of a vaccine, and most of the vaccines given in Bahrain are from Sinopharm. But the country is now seeing its worst wave of COVID-19 yet and the government has recently issued a two-week lockdown to try to get transmission under control.

The Seychelles went through a similar struggle. The archipelago saw a dramatic spike in cases in mid-May, despite having around 70 percent of its population vaccinated with at least one dose. Like Bahrain, the Seychelles had largely relied on the Sinopharm vaccine.

Dubai, which has also relied on Sinopharm’s vaccine, is now quietly offering residents who have been fully vaccinated with the Sinopharm vaccine the opportunity to get re-vaccinated with the Pfizer-BioNTech vaccine, according to The Wall Street Journal.

Source: Early adopters of Chinese vaccines see case surges; China plows ahead anyway | Ars Technica

新冠病毒能否诱导ADE效应?

那么,会有一个变种,专门针对疫苗产生的抗体有ADE效应的吗?

1622510044759428 480 320

  此次争论来自于一篇题为《抗体靶向的新冠病毒刺突蛋白上的感染增强位点》(An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies),5月24日发表在《细胞》杂志上。作者为大阪大学微生物疾病研究所免疫化学系Hisashi Arase等人。

  ADE效应,即抗体依赖性增强效应,最早由澳大利亚学者霍克斯于1964年提出,指的是病毒在感染细胞时,体内某些自然感染、接种疫苗、母体被动免疫获得的抗体非但不能提供保护效力,反而会增强病毒的感染能力,从而使病情加重。

  前述研究分离了74株新冠康复者的单克隆抗体,在体外细胞实验中进行测定后,发现其中6株抗体可增强新冠病毒与人体细胞的结合、4株抗体可加剧新冠病毒对细胞的感染。研究团队由此得出结论,在感染新冠病毒的过程中,具有抗病毒效力的“中和抗体”(neutralizing antibodies)和可以加剧病情的“增强抗体”(enhancing antibodies)都会产生。

  通过冷冻电镜结构解析,研究团队进一步确定了“增强抗体”的识别位点。6株增强抗体均为NTD抗体,通过与NTD上的特定位置结合,引发了病毒另一结构域RBD的构象变化,使RBD更易与人体细胞结合,从而加剧感染。

(略)

  学界此前曾不断猜测新冠病毒感染是否存在ADE效应。2020年4月,一名巴西男性居民被确诊轻症新冠肺炎,3天内康复,一个月后再次确诊,且病情更为严重,伴有高烧、咳嗽、头痛、嗅觉丧失等症状,CT显示肺部呈毛玻璃状。2020年5月,法国圣埃蒂安大学的研究团队报告了3例二次感染病例,均为第一次感染后康复、第二次病情恶化死亡。

  但何勇强调,体外实验中发现ADE效应并不等于临床上一定存在ADE效应,致病性是否增强不能在实验室的培养皿或试管里看到变化就完全证实,而应该观察二次感染时个体病情是否加重。

Source: 分析|新冠病毒能否诱导ADE效应?_财新网_财新网